Neuroleptic dosing in chronic schizophrenia: A 10-year follow-up

被引:16
作者
Remington, GJ
Prendergast, P
BezchlibnykButler, KZ
机构
[1] CLARKE INST PSYCHIAT,DEPT PHARM,TORONTO,ON M5T 1R8,CANADA
[2] WHITBY PSYCHIAT HOSP,WHITBY,ON,CANADA
来源
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | 1997年 / 42卷 / 01期
关键词
neuroleptic dosing; chronic schizophrenia; 10-year follow-up;
D O I
10.1177/070674379704200108
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To evaluate neuroleptic dosing patterns in individuals with schizophrenia over a IO-year interval Method: Changes in neuroleptic dosing between 1980 and 1990 were followed in 65 patients with a diagnosis of chronic schizophrenia. Results: According to more recent dosing guidelines, doses were already high at the time of initial evaluation, yet overall they continued to increase during the next decade of treatment for both males and females. Patients were almost equally divided, however, by those who underwent an increase (n=33) and those whose dose remained stable (n=4) or was decreased (n=28). Conclusion: A considerable number of patients with schizophrenia appear to receive progressively higher neuroleptic doses over the course of their illness, despite a lack of empirical data to support such an approach. Results are discussed in terms of current dosing recommendations and factors influencing dose changes.
引用
收藏
页码:53 / 57
页数:5
相关论文
共 47 条
[1]   GENDER DIFFERENCES IN AGE AT ONSET OF SCHIZOPHRENIA - AN OVERVIEW [J].
ANGERMEYER, MC ;
KUHN, L .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1988, 237 (06) :351-364
[2]   GENDER DIFFERENCES IN SCHIZOPHRENIA - REHOSPITALIZATION AND COMMUNITY SURVIVAL [J].
ANGERMEYER, MC ;
GOLDSTEIN, JM ;
KUEHN, L .
PSYCHOLOGICAL MEDICINE, 1989, 19 (02) :365-382
[3]   EFFECTS OF LONG-TERM ADMINISTRATION OF ANTIDEPRESSANTS AND NEUROLEPTICS ON RECEPTORS IN THE CENTRAL NERVOUS-SYSTEM [J].
BAKER, GB ;
GREENSHAW, AJ .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 1989, 9 (01) :1-44
[4]  
BALDESSARINI RJ, 1984, AM J PSYCHIAT, V141, P748
[5]  
BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P75
[6]  
BECKMANN H, 1990, ACTA PSYCHIAT SCAN S, V82, pS63
[7]  
BEZCHLIBNYKBUTL.KZ, 1988, CLIN HDB PSYCHOTROPI
[8]   HIGH DOSAGE HALOPERIDOL THERAPY IN CHRONIC-SCHIZOPHRENIC PATIENTS - DOUBLE-BLIND-STUDY OF CLINICAL-RESPONSE, SIDE-EFFECTS, SERUM HALOPERIDOL, AND SERUM PROLACTIN [J].
BJORNDAL, N ;
BJERRE, M ;
GERLACH, J ;
KRISTJANSEN, P ;
MAGELUND, G ;
OESTRICH, IH ;
WAEHRENS, J .
PSYCHOPHARMACOLOGY, 1980, 67 (01) :17-23
[9]   RESPONSE TO NEUROLEPTIC DRUGS AS A DEVICE FOR CLASSIFYING SCHIZOPHRENIA [J].
BROWN, WA ;
HERZ, LR .
SCHIZOPHRENIA BULLETIN, 1989, 15 (01) :123-129
[10]  
COHEN BM, 1989, ARCH GEN PSYCHIAT, V46, P381